CSIMarket Company Name, Ticker, Industry, else..
 
Volitionrx Limited  (NYSE: VNRX)
Other Ticker:  
 
 
Price: $0.5500 $0.01 1.047%
Day's High: $0.5599 Week Perf: -3.53 %
Day's Low: $ 0.53 30 Day Perf: -4.56 %
Volume (M): 290 52 Wk High: $ 1.02
Volume (M$): $ 159 52 Wk Avg: $0.66
Open: $0.55 52 Wk Low: $0.43



 Market Capitalization (Millions $) 48
 Shares Outstanding (Millions) 88
 Employees 11
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 1

Volitionrx Limited
Volitionrx Limited is a medical technology company that focuses on developing blood-based diagnostics for different types of cancer and other diseases. It aims to develop novel tests that can provide early detection and accurate diagnosis, which can help in improving patient outcomes. The company's flagship product is the Nu.Q blood-based diagnostic platform, which utilizes epigenetic biomarkers to detect various types of cancer. Volitionrx Limited is headquartered in Singapore and operates globally to bring its innovative diagnostic solutions to the market.


   Company Address: 1489 West Warm Springs Road Henderson 89014 NV
   Company Phone Number: 650?1351   Stock Exchange / Ticker: NYSE VNRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CDIO   -2.77%    
MYGN   -1.09%    
A   -1.42%    
ABT   -1.02%    
EXAS        0.97% 
HOLX   -0.57%    
• View Complete Report
   



Volitionrx Limited

Volitionrx Limited Sees Compelling Revenue Growth in Recent Fiscal Period

Volitionrx Limited, a company in the healthcare industry, has recently released its financial statements for the most recent fiscal period. These statements reveal both positive and negative changes in the company's financial performance and stock value.
One of the key highlights from the financial statements is the improvement in the company's loss per share. In the most recent fiscal period, Volitionrx Limited decreased its loss per share to $-0.10, compared to $-0.15 in the previous year. This indicates that the company has been able to control its expenses more effectively and reduce its losses. Additionally, the earnings per share also improved from $-0.12 per share in the prior financial reporting period.
Volitionrx Limited

Volitionrx Limited Reports Significant Loss Despite Revenue Increase

Volitionrx Limited's recent financial results give cause for concern and indicate a bearish outlook for the company. Despite reporting a strong revenue increase of 103.795% year-on-year, reaching $0.24 million, the company still suffered a significant loss of $-0.12. This suggests that the company's expenses may be outpacing its revenue growth, raising doubts about its ability to achieve profitability.
Comparing Volitionrx's revenue advancement in the fourth quarter of 2023 with its industry peers in the In Vitro & In Vivo Diagnostic Substances sector, the company fared well, with a 14.53% business advance. However, it should be noted that this quarter's revenue growth performance was substantially higher than the average achieved during the same period in the previous year, which saw a deficit of $-0.11 per share and a revenue surge of 47.674% from $0.17 million. This indicates a potential slowing of revenue growth, as the percentage increase is lower in comparison.
Volitionrx Limited

Volitionrx Limited's Stock Skyrockets, but Challenges Loom: A Closer Look at the Company's Financial Results and Future Prospects



Volitionrx Limited, a biomedical company that specializes in blood-based diagnostics, experienced a significant increase in its stock value over the past week and month. However, despite robust revenue growth, the company continues to face challenges. This article delves into Volitionrx Limited's recent financial results and analyzes how these factors may impact the company's future prospects.
Impressive Revenue Growth:
Volitionrx Limited reported a remarkable year-on-year revenue increase of 405.016% to $0.17 million in the most recent fiscal period. This surge indicates a strong demand for the company's blood-based diagnostic solutions. Such exponential revenue growth demonstrates a positive market reception of Volitionrx's products and services.
Volitionrx Limited

VNRX has failed to break-even despite the epic Surge in revenue at the VNRX over the most recent fiscal period

Volitionrx Limited, a leading company in the In Vitro & In Vivo Diagnostic Substances industry, recently reported a significant increase in revenue for the most recent fiscal period. The company's revenue rose by an impressive 444.149% year on year to $0.22 million. However, despite this remarkable revenue growth, the company's deficit has extended to $-0.14.
In comparison to its industry contemporaries, Volitionrx Limited has outpaced its competitors in terms of revenue growth. The In Vitro & In Vivo Diagnostic Substances industry as a whole experienced a 12.33% increase in revenue during the same period. This indicates that Volitionrx Limited has been able to capture a larger market share and generate more revenue than its peers.
Volitionrx Limited

Despite Revenue Surge, Volitionrx Limited Still Struggles to Attain Profitability by the End of Fiscal Year 2023

Volitionrx Limited is a biotechnology and pharmaceuticals company that has been making waves in the industry in recent years. While the company has experienced some losses over the last fiscal year, they have also seen significant revenue growth that points towards a promising future. In this article, we will explore Volitionrx Limited's recent financial report and what it means for the company moving forward.
According to the most recent financial report released by Volitionrx Limited, the company saw a loss per share of $-0.15 in the fiscal period ending on March 31, 2023. This represents an increase in loss per share when compared to the previous reporting season, where they reported a loss per share of $-0.13. While an increase in losses may seem concerning, it is important to note that Volitionrx Limited also reported significant revenue growth during this period.






Volitionrx Limited's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com